At 24 hours, the mean PRR was 87.5% for the multiple dose treatment and 93.7% for the single dose.
There was no indication of a dose-response effect of treatment on psychiatric adverse events in the only prophylaxis study with multiple dose treatment groups (WV15673/WV15697).
The results indicated that genistein had the potential to increase rat metabolism rate of imatinib in vivo after the multiple dose treatment.
Confirmation of antidiabetic activity and toxicity ameliorative role of S. cordata was investigated in a chronic multiple dose treatment study of fifteen days.
In the adjusted model (Table 4), the PRR at 12 hours was 32.7% with multiple dose treatment and 57.7% with single dose therapy, with severity of disease a significant covariate (OR = 19.5, p = 0.011).
A linear correlation was obtained between the rate of change in nucleolar size during multiple dose treatment with the series of platinum drugs and the time taken for the development of altered sensory nerve conduction velocity (r= 0.86; P< 0.024).
Furthermore, our results on therapy utilization suggest that this new radiopharmaceutical has a great potential as therapeutic agent for GBM as clearly showed by survival results in experiments carried out with single- and multiple-dose treatments.
In summary, the observed improvements on state and trait dimensions of attachment after a multiple-dose treatment with OT provide further evidence in support of a pivotal role of OT in promoting the experience of attachment.
Furthermore, systemic multiple-dose treatment is only cost-effective in patients with a serum beta-hCG level of <3,000 IU/l, or a single-dose treatment in patients with a serum beta-hCG level of <1,500 IU/l [7, 14, 15].
Each part comprised two periods: period 1, multiple-dose treatment with macitentan, and period 2, multiple-dose treatment with macitentan and Cs (part A) or multiple-dose treatment with macitentan and rifampin (part B).
A good response to both single- and multiple-dose treatment was observed in almost all cases.
